Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1996 Jan;55(1):73–75. doi: 10.1136/ard.55.1.73

Redundancy of conventional articular response variables used in juvenile chronic arthritis clinical trials.

N Ruperto 1, E H Giannini 1
PMCID: PMC1010087  PMID: 8572741

Abstract

OBJECTIVE--To estimate the degree of redundancy among articular response variables used routinely in juvenile chronic arthritis (JCA) clinical trials. METHODS--We obtained data from a large, computerised databank holding information from multiple clinical trials in children with JCA to determine Pearson correlation coefficients for changes from baseline values in articular response variables. All 508 JCA patients who entered the analysis of efficacy of the original trials were included in the present study. An r value of 0.7 or greater was considered evidence of colinearity. RESULTS--When changes in joint counts of articular manifestations were compared with changes in the respective severity scores (for example swollen joint count versus swelling severity score), the r values were always > or = 0.7. Three articular response variables related to the assessment of pain are all highly correlated with each other. The number of joints with active arthritis was correlated with the number of joints with swelling and the swelling score. Change in the overall severity score was highly correlated (r > or = 0.7) with change in nearly all articular response variables. CONCLUSIONS--Many endpoints reported in JCA trials are redundant, especially counts and scores of the same articular measure. Eliminating redundant variables would provide the same information with less complexity, and decrease the probability of statistical error and ambiguous results.

Full text

PDF
73

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson J. J., Felson D. T., Meenan R. F., Williams H. J. Which traditional measures should be used in rheumatoid arthritis clinical trials? Arthritis Rheum. 1989 Sep;32(9):1093–1099. doi: 10.1002/anr.1780320907. [DOI] [PubMed] [Google Scholar]
  2. Brewer E. J., Giannini E. H., Kuzmina N., Alekseev L. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial. N Engl J Med. 1986 May 15;314(20):1269–1276. doi: 10.1056/NEJM198605153142001. [DOI] [PubMed] [Google Scholar]
  3. Brewer E. J., Jr, Giannini E. H. Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. I. Design. J Rheumatol. 1982 Jan-Feb;9(1):109–113. [PubMed] [Google Scholar]
  4. Felson D. T., Anderson J. J., Boers M., Bombardier C., Chernoff M., Fried B., Furst D., Goldsmith C., Kieszak S., Lightfoot R. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993 Jun;36(6):729–740. doi: 10.1002/art.1780360601. [DOI] [PubMed] [Google Scholar]
  5. Felson D. T. Choosing a core set of disease activity measures for rheumatoid arthritis clinical trials. J Rheumatol. 1993 Mar;20(3):531–534. [PubMed] [Google Scholar]
  6. Giannini E. H., Brewer E. J., Jr, Kuzmina N., Shaikov A., Wallin B. Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The USA Pediatric Rheumatology Collaborative Study Group. The USSR Cooperative Children's Study Group. Arthritis Rheum. 1990 Apr;33(4):466–476. doi: 10.1002/art.1780330402. [DOI] [PubMed] [Google Scholar]
  7. Giannini E. H., Brewer E. J., Jr Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. II. Analysis and presentation of data. J Rheumatol. 1982 Jan-Feb;9(1):114–122. [PubMed] [Google Scholar]
  8. Giannini E. H., Brewer E. J., Kuzmina N., Shaikov A., Maximov A., Vorontsov I., Fink C. W., Newman A. J., Cassidy J. T., Zemel L. S. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med. 1992 Apr 16;326(16):1043–1049. doi: 10.1056/NEJM199204163261602. [DOI] [PubMed] [Google Scholar]
  9. Silverman E. D., Cawkwell G. D., Lovell D. J., Laxer R. M., Lehman T. J., Passo M. H., Zemel L. S., Giannini E. H. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J Rheumatol. 1994 Dec;21(12):2353–2358. [PubMed] [Google Scholar]
  10. Tugwell P., Boers M. OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction. J Rheumatol. 1993 Mar;20(3):528–530. [PubMed] [Google Scholar]
  11. van der Heijde D. M., van 't Hof M., van Riel P. L., van de Putte L. B. Validity of single variables and indices to measure disease activity in rheumatoid arthritis. J Rheumatol. 1993 Mar;20(3):538–541. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES